Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PUMA knows this is also tax harvesting season, and they can just sit there and absorb all the shares that anyone wants to sell because of that. The last 2 yrs this has been a brutal time for ENZC
Dr C hasn't Tweeted in 4 months, we know there is lots going on behind the scenes and with NDA's in place. One day you would think Charles will catch everyone off guard, when as you say he takes the muzzle off......lol
Probably right MAGA. Well, PUMA has once again brought the trading to a grinding hault. NITE has had a 500k BID @ .0421 now for hours, but want hit the BID with PUMA there I guess. Wonder if PUMA will just eventually scoop those up so they can move down.
MAGA, it does look like they are absorbing most of the vol on the BID, I thought a few times maybe they did a little on the ASK, buy right, almost all on the BID. Hence why they try to make a large spread so the seller will come down to the BID.
We know we have many NDA's with several different partners/collaboraters. Sharing quite a bit of our technology obviously. But I have no idea about the theory if they are buying, it must be on the BID.
How long can PUMA keep this stranglehold here MAGA? Completely in control here once again. Like you said, not really any retail interest, they'll keep doing what they've been doing now for months.
Onelavi is just an e-commerce website that is an arm/branch of NPI, which we hired to distribute, market, and sell our product. Obviously the goal is to get into other e-commerce websites like Amazon and Walmart, and then eventually into retail outlets. It's a process and it takes time to get into stores like Walgreens or CVS, but this is a good start and ENZC has such a large loyal community which definitely helps.
Fascinating watching PUMA operate here. Notice how they were getting ready to drop the BID down until a large BID came in @ .0440, so they raised the BID to stay ahead.
Wow, has it been that long since PUMA has been in control? I figured at least 2-3 weeks but time flies I guess......lol
Hey MAGA, after a little early vol this morning, looks like PUMA is right back firmly in control of the BID/ASK. How long has it been now since they've been in control? At least a couple weeks. All kinds of resistance here and not enough vol. You would want to see a nice slow increase in vol in order to break and hold the upcoming levels anyways, not a one day massive increase in vol and we moonshot, only to crash and burn.
I'm not arguing with you there, until we see something.
They have updated their company profile page with OTC markets, I believe that is all they are required to do. Has the new CEO/COO listed on there.
Where? They are not required to be sec reporting so they don't have to say anything.
Unfortunately in the OTC pinks there is no requirement like that. On the big boards yes, but not down here.
Yes, very nice to see Timing......This is a great start and hopefully we'll see it on amazon.com & walmart.com, along with some small retail outlets in the near future. Onelavi.com is just a e-commerce type of website, but you have to start somewhere. Can be tough to bring the type of product we have from overseas, but looks like all the hurdles have been cleared and we can finally start to begin sales here in the US.
I think you may have been thinking about the distributor, which is here in the US, called NPI.
https://nutricompany.com/
Foxi, IPF Immune is not being produced in the US, it's being produced by VetProm in Bulgaria, same company producing their ITV-1.
This is what also probably caused delays along with labeling/supply issues back in March. New international product, an immune modulator, during the pandemic, I'm sure drew a lot of scrutiny from the FDA. Looks like the issues have been resolved and they are ready to launch on Monday.
Lots of talk about it only being on Onelavi.com, but this is just the initial launch imo, and as time goes by and they can assess demand, they will hopefully grow into other retailers and markets.
Supplement market was never initially on the radar, but it's a huge market and it can hopefully generate revenue until they can profit from ITV-1 or Clone 3. Any revs will certainly be welcomed.
Yeah I hear ya. Hasn't been a Tweet or PR in a long time. Change of CEO, you would think that would at least warrant a PR.
Yeah it makes you wonder 2B....... Couple that with the way PUMA has been trading/accumulating, and you can see where I'm going with this.
Late Aug til Oct 1 seemed brutal almost everyday. Just seemed like the other mm knew what STXG was doing, selling, so they basically just put up tons of ASK walls and the price got walked down daily basically.
We actually broke the loooong term downtrend from Feb during the run to almost .08, and while we have retraced now like 50% from there, it seems different watching L2. I could be wrong but I don't see the sell at all cost pressure we had from STXG. And like we have talked about it before, this is with basically ZERO interest from retail. You can probably count on one hand how many green days and 10+ mil share days we've had this year. So if we can get back just some of the vol, say we start to avg around 15 mil shares for a little bit, and the buys outweigh the sells, I think you'll see we can move up pretty significantly.
IPF is a good start and audited fins will go a long way to get people back interested and restoring trust. And then you have toxicology and our animal mab partner. So all these can happen by the 1Q, but of course anything can happen.
Ok thx, appreciate the update when you find out something.
I also noticed that but I think he got you confused with someone else, and responded to your post about IPF talking about the auditor......lol
2b......Yes, that is a big BID, especially right now considering we are only doing 2-3 million in vol right now. Hard to predict anything, but this is what happens before ENZC starts to move. We kind of bottom out, selling drys up at certain sp, and then you see the big BIDS start to come in. Let's see how the next couple weeks play out here. Holding the high .03's is the key for now imo.
I hear ya MAGA, and these next couple weeks are always interesting this time of year. I doubt we hear much until then, maybe last week of December but probably not until January.
The drive down in sp from late Aug to Oct was mainly driven by STXG imo, selling tons of shares daily. They stopped selling and the sp went back up to around .08, but has now slowly but surely come back down as there is no support above the 200 dma. I think you have to look at small battles here, and not revisiting the previous lows made would be a start imo. But getting past these moving avgs, especially the 200 and getting them to act as support, is not something I've really seen out of any OTC stock in the last 18 months.
But yes the NITE BID could have just been retail, but you've also had PUMA seemingly hoarding shares now for awhile down here also. Nothing will change without way more vol than we are witnessing, but hopefully some things get unveiled soon, especially the audited fins and IPF, so we can turn that page.
MAGA, interesting 1.7 Million BID by NITE at the open yesterday @ .0390. Never got down there all day and they seemed to want to also accumulate shares, but the vol is obviously extremely low. Seems like some seller exhaustion at this pt in time, but definitely not a lot buying interest/pressure whatsoever. Everyone seems to be waiting on seeing some of the potential near term catalysts we have been waiting for.
Yes, the shares added were restricted and probably had to do with the new CEO taking over for Murray. But not sure until we see a new filing.
Would be nice to get a purchase order sometime soon for the generator. Not sure if you listened to the radio interview with a one of the board members, can't remember his name but, he mentioned getting a po within 2 weeks at that time, and that has been over 3 months ago now. I asked the IR guy he acted completely unaware of anything, said he was just returning from vacation but would ask Murray.
Ok thx. I thought the IR guy said he was in Las Vegas but I could be wrong on that. Just know he said they were still building product.
6959 Speedway Blvd. Ste. W101
Las Vegas NV 89115
______________________________
They are still making products as of last week in there Las Vegas facility. According to the IR guy.
Yeah your right, this a 30-40 yr scam in the making Pumper Stumper that you have so brilliantly uncovered in 2020, all because they never had the funding to go to clinic trials back the with Clone 3, which is widely known and public knowledge to everyone. Tell us something we don't know if you want to try to act cute/smart.
What does it matter and why would I need to answer that question? I know the history behind Bioclonetics, and if you are referring to this being around for decades, that means absolutely nothing to me at the present time.
Do you deny that the NIH & Dr Fauci trying to patent the same antibody that Dr Cotropia already patented in 1989? Where as Dr Fauci admitted it had "utility" & "commercial value"? But somehow miraculously they lose in court, and the NIH snubbs them for any funding? Clone 3 was shown to be 2.6x more effective than their antibody done by Los Alamitos.
Correct. I haven't been able to find much research on this, but obviously I'm trusting ENZC & Co to be correct when it comes to selling or making ITV-1 available in several countries in Africa with just toxicology testing. Which is massive news imo when that gets completed, which should be anytime now. Basically just as good as getting a drug approval in Europe or the US, same equivalent. Africa is where you want to be anyways with ITV-1, since it has the most number of people affected by it.
I don't have the exact date as I know it was initially tested in Belgium several years ago at least. This is what Samsung Biologics has produced for us now, the recombinant form of Clone 3, and is currently being tested. Next step is funding the animal trials.....
This was from Charles back in 2019 and the Bioclonetics days......
"We are actively, very actively pursuing a pharma partner who does not require the completion of animal trails before partnering in our technological development."
"We firmly believe that our recombinant testing and then animal trials of our antibodies will produce the necessary evidence for a pharma partner to fully embrace them."
They are currently doing efficacy testing in Europe now in vitro, and this is the information I'm sure they are sharing with potential partners, ie Regeneron & Eli Lilly.
Not just that Mutat, but in the case of ENZC, if/when they get an equity partner to go to animal trials for Clone 3, it will absolutely explode from these levels no doubt. Then of course it will retrace again and so on as we get through the clinical phases.
Audit Issues........
Originally ENZC put out a pr stating they were looking to hire a PCAOB auditor and eventually up list to the OTCQB back in Jan 2021. They hired Malone & Bailey in Feb 2021. So far so good. In June, ENZC was informed that instead of being a business combination, that it should have been a merger between them and Bioclonetics. Well, obviously a huge deal and with probably enormous consequences as far as tax purposes and such, ENZC was then required to also audit Bioclonetics for 2019 & 2020.
ENZC then contends that it should have always been a business combination, and hires a outside account consultant with specialties in this matter, Steve Heumann. The 3 sides apparently work things out, ENZC is transparent with all the information requested of them that the auditors and Steve need, so then it seemed just a matter of time. Hence the reason Dr C made the comment he thought it could be days to weeks when we see the audit, and that was early 2022. Months go by and nothing is happening, all the while Charles contends in his quarterly reports that there is no problems or further questions.
Now it's mid summer, and we find out that ENZC has let go of M&B and brought on a new auditor from Greis & Associates, Blaze Greis. The million dollar question is why? Why the switch after almost a year and half with M&B, and so much time and effort put into them getting this audit done? This is where you have to speculate, but my guess would be they simply were taking too long and just couldn't get it done for whatever reason. Do you wait longer if you are ENZC and stick with M&B to see it through? Or do you simply cut ties and hire someone else who you feel can get the job done in a timely manner? They ended up choosing the later.
So, moral of the story is ENZC was in a lose-lose situation at the time they let go M&B, knowing either way it would take a lot more time to get the audit done either way it went. Optically it looked bad, and investor confidence was lost.
But under no scenario do I believe this was a scam or Dr C was leading investors when he said days/weeks. This audit getting done is obviously huge to ENZC, definitely not required and voluntary on their part, but important enough that only a month after the business combination they were already thinking to get audited fins. When will the ever seemingly elusive audited fins come out? No definitive answer, but as long as Blaze has everything he needs from the co, and there are no remaining issues if any to be resolved, we should see them here fairly soon.
I also believe confidence can and will be restored here with ENZC, once they start selling IPF and audited fins are reported.
Forward looking statements are just that, and I think they always intend to paint the best case scenario if everything went perfectly. But I also believe the intent and determination is there to achieve all the milestones they have set out, just not in the exact timeframe that they have given. I think they have been more mindful of this overall, except for the latest one where they said IPF would be available in November.
And here is a little snippet from the article written about Clone 3 back in 2013......
Then, in August 2010, came another
landmark for Clone 3. The U.S. government’s
Los Alamos HIV Clinical Database published
a review of Clone 3 antibody’s capacity to bind
directly with the 2,229 (then) known strains
of HIV around the world. By searching the
surface (amino acid) composition of these
2,229 HIV isolates, Los Alamos found that
ninety-eight percent of them have an exact
match—or conservative amino-acid substitu-
tion—for the minimal essential “core” epitope
KLIC to which the CLONE 3 antibody binds.
In other words, Clone 3 epitope KLIC has
the potential to elicit, in active vaccination, a
protective antibody (“CLONE 3”) that broadly
neutralizes ninety-eight percent of all known
HIV strains. This is more than any other
vaccine candidate whose study results have
been published.
The reason why Dr Fauci and the NIH were going after this antibody because they knew the power it had, and more than likely they were just going to shelve it to continue with their policy of selling drugs and not a cure. Under oath we know that Dr Fauci said it had "utility" & "commercial value" at that time. But lucky Dr Cotropia beat them to the punch and had already patented Clone 3 in 1989, hence why the judge ruled in their favor since it had already been patented 10 yrs prior.
Hey Valuator, no problem and here you go. From the Bioclonetics former funding page which is no longer active.......
As we have earlier reported, our parent monoclonal antibody has been previously tested in 5 international labs and shown to effectively neutralize multiple HIV isolates (strains of the virus) (http://www.bioclonetics.com/validation.html). From the parent antibody, we have prepared the required recombinant antibodies, required by the FDA for use in patient therapy, and initial tests have been conducted at the Institute of Tropical Medicine, University of Antwerp, Belgium.
From these tests results, the effectiveness of our recombinant antibody as compared to all other anti-HIV monoclonal antibodies thus far produced by pharma and the NIH, our recombinant tested at 2.6 times more effective than the best no. 1 antibody – VRC01 – and 6 times more effective than the no. 2 next best anti-HIV monoclonal antibody – VRC01 – (both produced by Vaccine Research Center, in conjunction with the NIH). We are conducting additional tests on our recombinant antibodies at The Scripps Institute in California and at Responsive BioServices in Georgia.
Although it was a small trial size, ITV-1 was already successful in a phase 3 clinical trial in Bulgaria.
As far as Clone 3, the parent monoclonal antibody was shown to be 2.6x more powerful than the govt NIH antibody, hence the reason Fauci tried to basically steal it, but lost that battle. The new recombinant form of Clone 3 is shown to be 30x more powerful than the parent antibody.
So this is why your investing here imo. A drug that was already successful, but because of a host of reasons and some shady characters in Bulgaria, was never brought to market.
And then you have Clone 3, which showed amazing efficacy in vitro compared to anything else, but somehow never was able to get the funds necessary to bring the drug to market.
Brining any drug to market is a longshot, and it a very long arduous process even if successful. ENZC definitely has a shot, but the road and process will be a long and bumpy one, filled with many ups/downs along the way. It's impossible to judge the success/failure of ENZC when they have just started the race.
PCAOB AUDITORS
On January 11, 2021, the Company engaged Malone Bailey to perform the Audit for the years ended December 31, 2019 and 2020.
The Company completed the client approval process in early February. No unanswered accounting issues arose. It was determined in
June of 2021 that the Bioclonetics transaction, which closed in November of 2020, should be accounted for as a reverse merger rather
than a business combination and will be reported as such in the audited financials for ENZC. The requested change in accounting
method required the books and records of Bioclonetics to be audited for the years ended December 31, 2019 and 2020 in accordance
with GAAP standards by a PCAOB auditor. After the hiring of independent Accounting Consultants, it was determined that the
Companies did do a business combination not a reverse merger, and as of the time of this filing, the Company has provided all the
records and agreements, accounting memos and backup documentation requested by the consultant and the auditor. The Changes in
Accounting Method will result in amendments to the quarters ending March 31. 2021, June 30, 2021, and September 30, 2021
immediately upon completion of the audits. In July of 2022, the Company and Malone Bailey terminated their relationship. There
were no unresolved accounting or financial issues between the parties. Gries and Associates, LLC was retained on July 18, 2022, and
is in the process of completing the 2020-2021 audits.
9
Trading so thinly here but can't get any follow-up vol yet.